A clinical trial at the Royal Marsden reports early encouraging results for a “triple-action” cancer jab in patients with treatment-resistant head and neck cancer. According to the reporting, the treatment can lead to tumours disappearing entirely in some cases, while also shrinking cancers in others. The trial focuses on patients whose disease does not respond to standard therapies, and the findings are described as promising for that difficult-to-treat group. The coverage does not provide detailed figures on response rates, duration of effect, or the size and design of the study, and it does not include long-term safety outcomes. As presented, the results are based on trial observations at this stage and indicate potential anti-tumour activity, including complete tumour regression in certain patients. Further follow-up and additional reporting would be needed to confirm how durable the responses are and to establish the treatment’s safety and effectiveness compared with existing options.